DNA damage response inhibition
Update: 2017-07-28
Description
Dr Massimini speaks with ecancer at WIN 2017 about novel drugs suitable as monotherapy or in combination to inhibit DNA repair pathways in tumours.
He highlights VX970 / M6620, a novel drug affecting the ATR kinase pathway of DNA repair, as well as M3814 which is currently in assessment combined with radiotherapy, and considers class-associated toxicities of DNA repair pathway inhibition.
He highlights VX970 / M6620, a novel drug affecting the ATR kinase pathway of DNA repair, as well as M3814 which is currently in assessment combined with radiotherapy, and considers class-associated toxicities of DNA repair pathway inhibition.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
